<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-222-2-55-63</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-2582</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL GASTROENTEROLOGY</subject></subj-group></article-categories><title-group><article-title>Сравнительная информативность параметров контролируемого затухания (CAPc) и непрерывного контролируемого затухания (CAP) для различных стадий неалкогольной жировой болезни печени</article-title><trans-title-group xml:lang="en"><trans-title>Comparative value of controlled attenuation (CAPc) and continuous controlled attenuation (CAP) parameters for different stages of non-alcoholic fatty liver disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8099-8602</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гончаров</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Goncharov</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">thisalexis@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8896-5285</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сасунова</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sasunova</surname><given-names>A. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4417-8076</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исаков</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Isakov</surname><given-names>V. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУН «Федеральный исследовательский центр питания, биотехнологии и безопасности пищи»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research Center for Nutrition, Biotechnology and Food Safety</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>26</day><month>03</month><year>2024</year></pub-date><volume>0</volume><issue>2</issue><fpage>55</fpage><lpage>63</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гончаров А.А., Сасунова А.Н., Исаков В.А., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Гончаров А.А., Сасунова А.Н., Исаков В.А.</copyright-holder><copyright-holder xml:lang="en">Goncharov A.A., Sasunova A.N., Isakov V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/2582">https://www.nogr.org/jour/article/view/2582</self-uri><abstract><p>Цель: Сравнить эффективность использования новой технологии непрерывного параметра контролируемого затухания (CAPc) с контролируемым параметром затухания (CAPc) (CAP) совместимыми с вибрационно-контролируемой транзиентной эластографии (VCTE) в популяции пациентов с неалкогольной жировой болезнью печени (НАЖБП). Материалы и методы: проведён ретроспективный анализ базы данных пациентов (n=582), разделённых на 2 группы: группа НАЖБП (342), контрольная группа (n=240), сформированной в период с 2021 по 2023 год. Оценка VCTE с CAP проводилась при помощи 2-х эластографов FibroScan 530® и FibroScan 630 Expert®. Оценивались показатели биохимического анализа крови, липидного и углеводного обмена. Статистические расчёты проводились при помощи STATISTICA13.0 (StatSoft Inc., США). Результаты: При сравнении CAP с CAPc были выявлены статистические различия между CAP (264,7 ± 61,2) и CAPc (260,1 ± 57,4) (P&lt;0,0001); IQR CAP (36,4 ± 21,7) и IQR CAPc (13 ± 7,8) (P&lt;0,0001). При рассмотрении стадий стеатоза печени отличий выявлено не было (p=0,32). Была выявлена высокая степень корреляции между CAP и CAPc (R2=0,87). Анализ показал высокую чувствительность и специфичность CAPc по сравнению с CAP для S0: 85,2% и 88,5%; S3: 81,2% и 91,2% против стадий S1: 41,4% и 91,0%; S2: 25,0% и 93,7%. При анализе несовпадений было показано, что основная доля несовпадений приходится на интервал в пределах двух смежных стадий (одной для S0 и S3): S0-10,7%, S1-42,8%, S2-62,5%, S3-10,0%. Выводы: CAPc обладает высокой диагностической эффективностью, поскольку IQR CAPc оказался в 3 раза меньше, чем IQR CAP. С другой стороны, показатели CAPc и CAP сильно коррелировали, а стадии стеатоза печени, рассчитанные на основании CAPc и CAP статистически не отличаюсь, что говорит об эквивалентности результатов двух эластографов.</p></abstract><trans-abstract xml:lang="en"><p>Objective: To compare the efficacy of continuous controlled attenuation parameter (CAPc) compatible with vibration-controlled transient elastography (VCTE) versus standard controlled attenuation parameter (CAP) in a population of patients with non-alcoholic fatty liver disease (NAFLD). Materials and methods: A retrospective analysis of the database of patients (n = 582), divided into two groups: NAFLD group (n = 342) and control group (n = 240), was performed. The database was formed in the period from 2021 to 2023. The assessment of VCTE with CAP was carried out using two elastographs (FibroScan 530® and FibroScan 630 Expert®). The indicators of biochemical blood test, lipid and carbohydrate metabolism were evaluated. Statistical calculations were performed using STATISTICA13.0 (StatSoftInc., USA). Results: When comparing CAP with CAPc, statistical differences between CAP (264.7 ± 61.2) and CAPc (260.1 ± 57.4) (P &lt; 0.0001), IQRCAP (36.4 ± 21.7) and IQR CAPc (13 ± 7.8) (P&lt;0.0001) were found. When considering the stages of liver steatosis, no differences were found (p=0.32). A high degree of correlation was found between CAP and CAPc (R2=0,87). The analysis showed high sensitivity and specificity of CAPc compared to CAP for S0 (85.2% and 88.5%) and S3 (81.2% and 91.2%) stages vs S1 (41.4% and 91.0%) and S2 (25.0% and 93.7%) stages. When analyzing mismatches, it was shown that the main share of mismatches falls within the interval between two adjacent stages (one for S0 and one for S3): S0: 10.7%, S1: 42.8%, S26 62.5% and S3: 10.0%. Conclusion: Since IQR CAPc is 3 times less than IQR CAP, CAPc has high diagnostic efficiency. On the other hand, CAPc and CAP scores are highly correlated, and the stages of liver steatosis calculated with CAPc and CAP are not statistically different, which indicates the equivalence of the results of two elastographs.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>неалкогольная жировая болезнь печени</kwd><kwd>транзиентная эластография</kwd><kwd>контролируемый параметр затухания</kwd><kwd>VCTE</kwd><kwd>CAP</kwd></kwd-group><kwd-group xml:lang="en"><kwd>non-alcoholic fatty liver disease</kwd><kwd>transient elastography</kwd><kwd>controlled attenuation parameter</kwd><kwd>VCTE</kwd><kwd>CAP</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zoonosis Z. M., Golabi P., Paik J. M., Henry A., Van Dongen C., Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004.</mixed-citation><mixed-citation xml:lang="en">Zoonosis Z. M., Golabi P., Paik J. M., Henry A., Van Dongen C., Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Younossi Z. M., Koenig A. B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431.</mixed-citation><mixed-citation xml:lang="en">Younossi Z. M., Koenig A. B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Le M. H., Yeo Y. H., Li X. et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis [published online ahead of print, 2021 Dec 7]. ClinGastroenterolHepatol. 2021; S1542-3565(21)01280-5. doi: 10.1016/j.cgh.2021.12.002.</mixed-citation><mixed-citation xml:lang="en">Le M. H., Yeo Y. H., Li X. et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis [published online ahead of print, 2021 Dec 7]. ClinGastroenterolHepatol. 2021; S1542-3565(21)01280-5. doi: 10.1016/j.cgh.2021.12.002.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mitra S., De A., Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. TranslGastroenterolHepatol. 2020;5:16. Published 2020 Apr 5. doi: 10.21037/tgh.2019.09.08.</mixed-citation><mixed-citation xml:lang="en">Mitra S., De A., Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. TranslGastroenterolHepatol. 2020;5:16. Published 2020 Apr 5. doi: 10.21037/tgh.2019.09.08.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ciardullo S., Grassi G., Mancia G., Perseghin G. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. Eur J GastroenterolHepatol. 2022;34(4):365-371. doi: 10.1097/MEG.0000000000002299.</mixed-citation><mixed-citation xml:lang="en">Ciardullo S., Grassi G., Mancia G., Perseghin G. Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis. Eur J GastroenterolHepatol. 2022;34(4):365-371. doi: 10.1097/MEG.0000000000002299.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Alon L., Corica B., Raparelli V. et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J PrevCardiol. 2022;29(6):938-946. doi: 10.1093/eurjpc/zwab212.</mixed-citation><mixed-citation xml:lang="en">Alon L., Corica B., Raparelli V. et al. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J PrevCardiol. 2022;29(6):938-946. doi: 10.1093/eurjpc/zwab212.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mantovani A., Petracca G., Beatrice G. et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2022;71(4):778-788. doi: 10.1136/gutjnl-2021-324191.</mixed-citation><mixed-citation xml:lang="en">Mantovani A., Petracca G., Beatrice G. et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. Gut. 2022;71(4):778-788. doi: 10.1136/gutjnl-2021-324191.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lazebnik L. B., Golovanova E. V., Turkina S. V. et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52.(In Russ.) doi: 10.31146/1682-8658-ecg-185-1-4-52.@@ Лазебник Л. Б., Голованова Е. В., Туркина С. В. И соавт. Неалкогольная жировая болезнь печени у взрос лых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;185(1): 4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52.</mixed-citation><mixed-citation xml:lang="en">Lazebnik L. B., Golovanova E. V., Turkina S. V. et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52.(In Russ.) doi: 10.31146/1682-8658-ecg-185-1-4-52.@@ Лазебник Л. Б., Голованова Е. В., Туркина С. В. И соавт. Неалкогольная жировая болезнь печени у взрос лых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;185(1): 4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ivashkin V. T., Mayevskaya M. V., Pavlov Ch.S., FedosyinaYe.A., BessonovaYe.N., Pirogova I.Yu., Garbuzenko D. V. Treatment of liver cirrhosis complications: Clinical guidelines of the Russian Scientific Liver Society and Russian gastroenterological association. Ross z gastroenterolgepatolkoloproktol. 2016;26(4):71-102. doi: 10.22416/1382-4376-2016-26-4-71-102.@@ Ивашкин В. Т., Маевская М. В., Павлов Ч. С., Федосьина Е. А., Бессонова Е. Н., Пирогова И. Ю., Гарбузенко Д. В. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российскийжурналгастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):71-102. doi: 10.22416/1382-4376-2016-26-4-71-102.</mixed-citation><mixed-citation xml:lang="en">Ivashkin V. T., Mayevskaya M. V., Pavlov Ch.S., FedosyinaYe.A., BessonovaYe.N., Pirogova I.Yu., Garbuzenko D. V. Treatment of liver cirrhosis complications: Clinical guidelines of the Russian Scientific Liver Society and Russian gastroenterological association. Ross z gastroenterolgepatolkoloproktol. 2016;26(4):71-102. doi: 10.22416/1382-4376-2016-26-4-71-102.@@ Ивашкин В. Т., Маевская М. В., Павлов Ч. С., Федосьина Е. А., Бессонова Е. Н., Пирогова И. Ю., Гарбузенко Д. В. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по лечению осложнений цирроза печени. Российскийжурналгастроэнтерологии, гепатологии, колопроктологии. 2016;26(4):71-102. doi: 10.22416/1382-4376-2016-26-4-71-102.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Clinical guidelines from 2021 “Chronic viral hepatitis C”. Available at: https://medi.ru/klinicheskie-rekomendatsii/khronicheskij-virusnyj-gepatit-s-khvgs-u-vzroslykh_14028/Accessed: 05/17/2023.@@ Клинические рекомендации от 2021 г. «Хронический вирусный гепатит С». ссылка активна на 17.05.2023. https://medi.ru/klinicheskie-rekomendatsii/khronicheskij-virusnyj-gepatit-s-khvgs-u-vzroslykh_14028/</mixed-citation><mixed-citation xml:lang="en">Clinical guidelines from 2021 “Chronic viral hepatitis C”. Available at: https://medi.ru/klinicheskie-rekomendatsii/khronicheskij-virusnyj-gepatit-s-khvgs-u-vzroslykh_14028/Accessed: 05/17/2023.@@ Клинические рекомендации от 2021 г. «Хронический вирусный гепатит С». ссылка активна на 17.05.2023. https://medi.ru/klinicheskie-rekomendatsii/khronicheskij-virusnyj-gepatit-s-khvgs-u-vzroslykh_14028/</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Oeda S., Tanaka K., Oshima A., Matsumoto Y., Sueoka E., Takahashi H. Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. Diagnostics (Basel). 2020;10(11):940. Published 2020 Nov 12. doi: 10.3390/diagnostics10110940.</mixed-citation><mixed-citation xml:lang="en">Oeda S., Tanaka K., Oshima A., Matsumoto Y., Sueoka E., Takahashi H. Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. Diagnostics (Basel). 2020;10(11):940. Published 2020 Nov 12. doi: 10.3390/diagnostics10110940.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sasso M., Beaugrand M., de Ledinghen V. et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825-1835. doi: 10.1016/j.ultrasmedbio.2010.07.005.</mixed-citation><mixed-citation xml:lang="en">Sasso M., Beaugrand M., de Ledinghen V. et al. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825-1835. doi: 10.1016/j.ultrasmedbio.2010.07.005.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Selvaraj E. A., Mózes F. E., Jayaswal A. N.A. et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2021;75(4):770-785. doi: 10.1016/j.jhep.2021.04.044.</mixed-citation><mixed-citation xml:lang="en">Selvaraj E. A., Mózes F. E., Jayaswal A. N.A. et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol. 2021;75(4):770-785. doi: 10.1016/j.jhep.2021.04.044.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Pu K., Wang Y., Bai S. et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):51. Published 2019 Apr 8. doi: 10.1186/s12876-019-0961-9.</mixed-citation><mixed-citation xml:lang="en">Pu K., Wang Y., Bai S. et al. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):51. Published 2019 Apr 8. doi: 10.1186/s12876-019-0961-9.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang W., Huang S., Teng H. et al. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open. 2018;8(8): e021787. Published 2018 Aug 23. doi: 10.1136/bmjopen-2018-021787.</mixed-citation><mixed-citation xml:lang="en">Jiang W., Huang S., Teng H. et al. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open. 2018;8(8): e021787. Published 2018 Aug 23. doi: 10.1136/bmjopen-2018-021787.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang X., Wong G. L., Wong V. W. Application of transient elastography in nonalcoholic fatty liver disease. ClinMolHepatol. 2020;26(2):128-141. doi: 10.3350/cmh.2019.0001n.</mixed-citation><mixed-citation xml:lang="en">Zhang X., Wong G. L., Wong V. W. Application of transient elastography in nonalcoholic fatty liver disease. ClinMolHepatol. 2020;26(2):128-141. doi: 10.3350/cmh.2019.0001n.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tsochatzis E. A., Gurusamy K. S., Ntaoula S., Cholongitas E., Davidson B. R., Burroughs A. K. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650-659. doi: 10.1016/j.jhep.2010.07.033.</mixed-citation><mixed-citation xml:lang="en">Tsochatzis E. A., Gurusamy K. S., Ntaoula S., Cholongitas E., Davidson B. R., Burroughs A. K. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54(4):650-659. doi: 10.1016/j.jhep.2010.07.033.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Karlas T., Petroff D., Sasso M. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022.</mixed-citation><mixed-citation xml:lang="en">Karlas T., Petroff D., Sasso M. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi: 10.1016/j.jhep.2016.12.022.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Castéra L., Vergniol J., Foucher J. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-350. doi: 10.1053/j.gastro.2004.11.018.</mixed-citation><mixed-citation xml:lang="en">Castéra L., Vergniol J., Foucher J. et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-350. doi: 10.1053/j.gastro.2004.11.018.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hartl J., Denzer U., Ehlken H. et al. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. J Hepatol. 2016;65(4):769-775. doi: 10.1016/j.jhep.2016.05.023.</mixed-citation><mixed-citation xml:lang="en">Hartl J., Denzer U., Ehlken H. et al. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. J Hepatol. 2016;65(4):769-775. doi: 10.1016/j.jhep.2016.05.023.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Corpechot C., Carrat F., Poujol-Robert A. et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56(1):198-208. doi: 10.1002/hep.25599.</mixed-citation><mixed-citation xml:lang="en">Corpechot C., Carrat F., Poujol-Robert A. et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56(1):198-208. doi: 10.1002/hep.25599.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Nogami A., Iwaki M., Kobayashi T. et al. Real-world assessment of SmartExam, a novel FibroScan computational method: A retrospective single-center cohort study. J GastroenterolHepatol. 2023;38(2):321-329. doi: 10.1111/jgh.16076.</mixed-citation><mixed-citation xml:lang="en">Nogami A., Iwaki M., Kobayashi T. et al. Real-world assessment of SmartExam, a novel FibroScan computational method: A retrospective single-center cohort study. J GastroenterolHepatol. 2023;38(2):321-329. doi: 10.1111/jgh.16076.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Chan W. K., Nik Mustapha N. R., Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J GastroenterolHepatol. 2014;29(7):1470-1476. doi: 10.1111/jgh.12557.</mixed-citation><mixed-citation xml:lang="en">Chan W. K., Nik Mustapha N. R., Mahadeva S. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J GastroenterolHepatol. 2014;29(7):1470-1476. doi: 10.1111/jgh.12557.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
